These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31482429)

  • 21. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
    Santhanam P; Taïeb D
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET Imaging in Recurrent Medullary Thyroid Carcinoma.
    Treglia G; Rufini V; Salvatori M; Giordano A; Giovanella L
    Int J Mol Imaging; 2012; 2012():324686. PubMed ID: 22852077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
    Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
    Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature.
    Gotthardt M; Battmann A; Höffken H; Schurrat T; Pollum H; Beuter D; Gratz S; Béhé M; Bauhofer A; Klose KJ; Behr TM
    Nucl Med Commun; 2004 May; 25(5):439-43. PubMed ID: 15100501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
    Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
    J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis.
    Treglia G; Cocciolillo F; Di Nardo F; Poscia A; de Waure C; Giordano A; Rufini V
    Acad Radiol; 2012 Oct; 19(10):1290-9. PubMed ID: 22819076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals.
    Wong KK; Laird AM; Moubayed A; Chondrogiannis S; Marzola MC; Evangelista L; Gross MD; Rubello D
    Nucl Med Commun; 2012 Jul; 33(7):679-88. PubMed ID: 22422100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.
    Khan N; Oriuchi N; Higuchi T; Endo K
    Cancer Control; 2005 Oct; 12(4):254-60. PubMed ID: 16258498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer.
    Jiang J; Yang Z; Zhang Y; Xu X; Wang M; Hu S; Yao Z; Pan H; Zhang Y; Li D
    Clin Imaging; 2014; 38(6):797-801. PubMed ID: 24973077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.
    Rufini V; Castaldi P; Treglia G; Perotti G; Gross MD; Al-Nahhas A; Rubello D
    Biomed Pharmacother; 2008 Mar; 62(3):139-46. PubMed ID: 17892924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
    De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
    Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
    Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
    Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
    Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
    Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy.
    Giovanella L; Avram AM; Iakovou I; Kwak J; Lawson SA; Lulaj E; Luster M; Piccardo A; Schmidt M; Tulchinsky M; Verburg FA; Wolin E
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2514-2525. PubMed ID: 31392371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.